Effort is not always the limiting variable.
A high-scrutiny compounded IGF-1 LR3 prescription with serious clinician review and ongoing monitoring.
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products. ## Updated copy: Longevity, Mind and Performance Peptides
About 10 minutes. No charge unless your clinician approves.
Growth hormone gets the credit. IGF-1 carries the signal.
Recovery gets frustrating when the inputs are disciplined and the tissue is still lagging. Adding more work does not solve a signaling bottleneck. IGF-1 LR3 is built around the signal downstream of the work.
Growth hormone tells the liver to produce IGF-1, and IGF-1 is the signal that reaches muscle and connective tissue and tells them to grow. Most circulating IGF-1 is bound to carrier proteins, so LR3 is modified around that constraint. In cells that produce binding proteins, research found LR3 substantially more potent than ordinary IGF-1; in cells that do not, it was less potent, pointing to carrier evasion rather than stronger receptor binding as the advantage.1 Research also found LR3 clears from blood considerably faster than ordinary IGF-1, not slower.2
IGF-1 LR3 is not a shortcut. Glucose risk, candidacy screening, timing, and monitoring make the medical care around a potent signal more important than access to a vial.
For when effort stopped being the limiting factor.
Same Discipline, Different Return
Training and nutrition still look like yours. The recovery you get from them does not. You are looking past motivation because motivation is clearly not the problem.
The Time Between Sessions Is the Limiter
You can still produce the work. What has changed is how much rebuilding has to happen before your body is ready to ask for it again.
The Rebuild Became Its Own Project
Injury or illness took tissue out of the picture, and getting it back has become more complicated than simply resuming the old routine.
Compounded IGF-1 LR3 is not an FDA-approved drug product. Whether it is appropriate for you is determined by a licensed provider from your full Assessment.
This might not be the right fit if:
- Active or suspected malignancy, or a history of cancer without oncology clearance
- Pregnancy or breastfeeding
- Known hypersensitivity to any component of the preparation
- Under 18
- Diabetes, prediabetes, or any medication that lowers blood sugar, without clearance from the clinician managing it
- A history of low blood sugar episodes
- Competing in a tested sport, unless you have confirmed the position with your governing body
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
IGF-1 LR3, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- A modified form of the IGF-1 signal, compounded to your individual prescription by a licensed US pharmacy
- A licensed provider reviews your history, medications, recovery pattern, and full plan before prescribing
- Dose and duration are individualized, with follow-up built into the plan
- Provider review, the prescription if approved, pharmacy, and shipping handled inside one plan.
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products. ## Updated copy: Longevity, Mind and Performance Peptides
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Recovery & Repair.
BPC-157
The peptide everyone asks about, inside real medicine.
Compounded BPC-157 sourced through a licensed US pharmacy and placed inside clinician review, not a research-vendor checkout.
BPC-157 Oral
A capsule that meets the digestive tract directly.
Compounded oral BPC-157 delivered directly into the digestive tract, with a clinician deciding whether capsule or injection fits the case.
Wolverine Stack
Two repair pathways. One prescription.
A compounded BPC-157 and TB-500 prescription pairing BPC-157's tissue-repair signaling with thymosin beta-4 biology in cell movement and wound closure.
Do not use if you have
- Active or suspected malignancy
Serious risks
- IGF-1 acts on the same receptor family as insulin, so the most immediate risk is low blood sugar
- Sustained use suppresses your own growth hormone and IGF-1 production, so duration is planned rather than open-ended
- IGF-1 signaling drives cell growth generally, which means any history of cancer requires oncology clearance
- Prohibited at all times by the World Anti-Doping Agency, in and out of competition
This one carries real risk and the screening is not a formality. That is why your provider sets timing around food, and why any diabetes diagnosis or glucose-lowering medication has to be on your intake. Human safety data for this analogue is limited, which is the reason this sits with a clinician rather than in a shopping cart.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
IGF-1 signaling intersects with growth and glucose regulation, and hypoglycemia is a meaningful risk. Baseline history, current medications, glucose status, and follow-up matter more here than a universal timeline. Serious screening and monitoring belong around the prescription from the beginning.
IGF-1 is an approved medicine in the United States, prescribed as Increlex for people whose bodies do not produce enough of it on their own. IGF-1 LR3 is a modified form of that same signal, built to stay free in the blood rather than bound up by carrier proteins. No compounded medication is FDA-approved, including this one. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.
IGF-1 LR3 is exactly the kind of molecule that should make you want more medical context, not less. Here, a licensed provider reviews whether it belongs in your care and a licensed US pharmacy compounds it to an individual prescription. The FDA has found products sold as research chemicals under false labels, some naming compounding pharmacies that do not exist, and warns they “can pose risks of serious harm” by bypassing the body’s defenses.F4 Testing has found wide variation in purity and in how much of the compound is actually in the vial. AnthologyRX+ puts a prescriber, pharmacy of record, and follow-up plan around a biologically powerful signal. That is the difference between access and medicine.
Any time, before your renewal date. No phone calls required.
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, and FDA Warning Letter to Gram Peptides, March 31, 2026.